What does Celcuity's new FDA‑approved breast cancer drug mean for the company?

Celcuity’s newly approved small molecule inhibitor for breast cancer marks its transition from a development‑stage biotech to a commercial player. The drug’s blockbuster potential makes it a likely target for major pharmaceutical partnerships or acquisitions, while its pricing and label scope will determine its real impact in oncology markets.